360 related articles for article (PubMed ID: 17890448)
1. Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling.
Isenberg JS; Romeo MJ; Yu C; Yu CK; Nghiem K; Monsale J; Rick ME; Wink DA; Frazier WA; Roberts DD
Blood; 2008 Jan; 111(2):613-23. PubMed ID: 17890448
[TBL] [Abstract][Full Text] [Related]
2. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1.
Isenberg JS; Ridnour LA; Dimitry J; Frazier WA; Wink DA; Roberts DD
J Biol Chem; 2006 Sep; 281(36):26069-80. PubMed ID: 16835222
[TBL] [Abstract][Full Text] [Related]
3. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.
Kirkby NS; Lundberg MH; Chan MV; Vojnovic I; Solomon AB; Emerson M; Mitchell JA; Warner TD
Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15782-7. PubMed ID: 24003163
[TBL] [Abstract][Full Text] [Related]
4. Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake.
Isenberg JS; Jia Y; Fukuyama J; Switzer CH; Wink DA; Roberts DD
J Biol Chem; 2007 May; 282(21):15404-15. PubMed ID: 17416590
[TBL] [Abstract][Full Text] [Related]
5. Towards the Therapeutic Use of Thrombospondin 1/CD47 Targeting TAX2 Peptide as an Antithrombotic Agent.
Jeanne A; Sarazin T; Charlé M; Kawecki C; Kauskot A; Hedtke T; Schmelzer CEH; Martiny L; Maurice P; Dedieu S
Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):e1-e17. PubMed ID: 33232198
[TBL] [Abstract][Full Text] [Related]
6. Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin-induced platelet shape change.
Jensen BO; Kleppe R; Kopperud R; Nygaard G; Døskeland SO; Holmsen H; Selheim F
Platelets; 2011; 22(1):8-19. PubMed ID: 20958117
[TBL] [Abstract][Full Text] [Related]
7. Association of thrombospondin-1 with the actin cytoskeleton of human thrombin-activated platelets through an alphaIIbbeta3- or CD36-independent mechanism.
Saumet A; de Jesus N; Legrand C; Dubernard V
Biochem J; 2002 May; 363(Pt 3):473-82. PubMed ID: 11964147
[TBL] [Abstract][Full Text] [Related]
8. Platelet aggregation induced by the C-terminal peptide of thrombospondin-1 requires the docking protein LAT but is largely independent of alphaIIb/beta3.
Trumel C; Plantavid M; Lévy-Tolédano S; Ragab A; Caen JP; Aguado E; Malissen B; Payrastre B
J Thromb Haemost; 2003 Feb; 1(2):320-9. PubMed ID: 12871507
[TBL] [Abstract][Full Text] [Related]
9. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function.
Aszódi A; Pfeifer A; Ahmad M; Glauner M; Zhou XH; Ny L; Andersson KE; Kehrel B; Offermanns S; Fässler R
EMBO J; 1999 Jan; 18(1):37-48. PubMed ID: 9878048
[TBL] [Abstract][Full Text] [Related]
10. Vasodilator-Stimulated Phosphoprotein (VASP)-dependent and -independent pathways regulate thrombin-induced activation of Rap1b in platelets.
Benz PM; Laban H; Zink J; Günther L; Walter U; Gambaryan S; Dib K
Cell Commun Signal; 2016 Sep; 14(1):21. PubMed ID: 27620165
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells.
Isenberg JS; Yu C; Roberts DD
Biochem Pharmacol; 2008 Feb; 75(4):875-82. PubMed ID: 18068687
[TBL] [Abstract][Full Text] [Related]
12. Dual regulation of glycogen synthase kinase 3 (GSK3)α/β by protein kinase C (PKC)α and Akt promotes thrombin-mediated integrin αIIbβ3 activation and granule secretion in platelets.
Moore SF; van den Bosch MT; Hunter RW; Sakamoto K; Poole AW; Hers I
J Biol Chem; 2013 Feb; 288(6):3918-28. PubMed ID: 23239877
[TBL] [Abstract][Full Text] [Related]
13. Platelet regulation by NO/cGMP signaling and NAD(P)H oxidase-generated ROS.
Begonja AJ; Teichmann L; Geiger J; Gambaryan S; Walter U
Blood Cells Mol Dis; 2006; 36(2):166-70. PubMed ID: 16469512
[TBL] [Abstract][Full Text] [Related]
14. Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses.
Isenberg JS; Wink DA; Roberts DD
Cardiovasc Res; 2006 Sep; 71(4):785-93. PubMed ID: 16820142
[TBL] [Abstract][Full Text] [Related]
15. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
16. The NO/cGMP pathway inhibits Rap 1 activation in human platelets via cGMP-dependent protein kinase I.
Danielewski O; Schultess J; Smolenski A
Thromb Haemost; 2005 Feb; 93(2):319-25. PubMed ID: 15711749
[TBL] [Abstract][Full Text] [Related]
17. High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets.
Russo I; Viretto M; Barale C; Mattiello L; Doronzo G; Pagliarino A; Cavalot F; Trovati M; Anfossi G
Diabetes; 2012 Nov; 61(11):2913-21. PubMed ID: 22837307
[TBL] [Abstract][Full Text] [Related]
18. A noble function of BAY 11-7082: Inhibition of platelet aggregation mediated by an elevated cAMP-induced VASP, and decreased ERK2/JNK1 phosphorylations.
Lee HS; Kim SD; Lee WM; Endale M; Kamruzzaman SM; Oh WJ; Cho JY; Kim SK; Cho HJ; Park HJ; Rhee MH
Eur J Pharmacol; 2010 Feb; 627(1-3):85-91. PubMed ID: 19913011
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic activities of ferulic acid via intracellular cyclic nucleotide signaling.
Hong Q; Ma ZC; Huang H; Wang YG; Tan HL; Xiao CR; Liang QD; Zhang HT; Gao Y
Eur J Pharmacol; 2016 Apr; 777():1-8. PubMed ID: 26948317
[TBL] [Abstract][Full Text] [Related]
20. Nitric oxide inhibits platelet adhesion to collagen through cGMP-dependent and independent mechanisms: the potential role for S-nitrosylation.
Irwin C; Roberts W; Naseem KM
Platelets; 2009 Nov; 20(7):478-86. PubMed ID: 19852686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
